Background: The aim of this study was to investigate aspects of metabolic control, treatment and complications as well as quality of life in patients with diabetes mellitus from a defined population in Estonia. Methods: We invited 220 randomly selected diabetes patients recruited to a clinical investigation from a local diabetes register of 1,100 patients in Viljandi, Estonia. The main outcome measures were derived from medical history, physical examination (height, weight and blood pressure), laboratory variables (blood glucose and glycated haemoglobin Ai (HbAi normal reference range 3.2-5.6%), serum total and HDL cholesterol and creatinine), a questionnaire on disease-related knowledge and quality of life variables. Results: In all, 181 diabetes patients were investigated, of whom 90% were diagnosed with type 2 diabetes. The mean diabetes duration was 8.9 years from clinical diagnosis and mean HbAi level was 7.3%. The overall proportion of patients treated with Insulin was 29.8% and with anti-hypertensive drugs 26.5%. Smoking was present in 14.3%. The proportion of patients with various diabetes complications was high (73.5%), mostly consisting of different manifestations of cardiovascular disease. Foot ulcers or gangrene were observed in 11.6%. A low level of quality of life was registered in many patients, mostly due to difficult living conditions. Conclusions: Diabetes patients in Viljandi showed an acceptable degree of glucose metabolic control, but reported a high degree of diabetes complications, as well as impaired quality of life. The diabetes complications may therefore be due to detrimental factors other than hyperglycaemia, e.g. the standard of care during previous years as well as current social and living conditions.
Di abetes mellitus and cardiovascular disease are major public health problems in Estonia, as well as in the other Nordic countries. The prevalence and incidence of type 1 diabetes around the Baltic Sea is better known than that of type 2 diabetes. The incidence and prevalence of type 1 diabetes is reported to be lower in Estonia than in Sweden and Finland and is estimated to be stable at a level of approximately one-third of that which has been reported from Finland. ' However, not very much is known about the incidence and prevalence of type 2 diabetes in Estonia. It is well-known that type 2 diabetes and cardiovascular disease often co-exist. In Estonia, the incidence of acute myocardtal infarction is high, 4 as well as mortality from cardiovascular disease. 5 This prevalence has been high over the last 20 years and in 1990 was estimated to be approximately three times higher than that of corresponding Swedish males in the same age group. The same relations exist for females but at a level of approximately one-third of the mortality rate in males. Howver, no specific figures exist for cardiovascular mortality in Estonian diabetes patients.
In 1991 Estonia joined die St Vincent Declaration with the objective of improving the quality of diabetes care, as well as consequently reducing die incidence and severity of diabetes complications and developing a national programme for achieving this. 6 The process of implementation of the goals of the St Vincent Declaration requires a good baseline knowledge of the diabetes patient population and of the organisation, contacts and quality of the care given to rhis population. The level of metabolic control and living conditions for Estonian diabetes patients have so far not been well-described. This is requested as an integrated part of the screening procedures in order to enable it to reach the goals of the St Vincent Declaration. In a joint Swedish-Estonian research project this was investigated during the years 1993-1995 in the Estonian city of Viljandi. The general aim of the project was to improve the standard of care given to patients with diabetes mellitus in Viljandi and to initiate a computerised diabetes register. The specific aims of rhis study report were to estimate the quality of life of the patients, determine the level of metabolic control and quantify the prevalence of complications in diabetes patients and their risk factors.
MATERIAL AND METHODS

Study area and study popidation
Viljandi county is located in the southern part of Estonia. It has a population of 65,000 inhabitants, of whom 26,000 live in the central city of Viljandi and 39,000 in the Downloaded from https://academic.oup.com/eurpub/article-abstract/11/1/60/447301 by guest on 08 March 2019 surrounding county. The population is rather stable and ethnically homogenous, being of Estonian origin. There is one central hospital and one city policlinic in Viljandi county, as well as some smaller health centres in the countryside. The same administration exists for both the hospital and the city policlinic. Diabetes patients from Viljandi, as well as most diabetics from the surrounding countryside, are regularly examined by a trained diabetologist (H.V.) at least annually. Anti-diabetic and antihypertensive drugs are available but may be expensive for many patients and, therefore, not taken on a completely regular basis. For example, the cost of the antidiabetic drug metformin is presently not reimbursed by the health authorities, as are the costs of sulphonylureas and insulin treatment. One-fifth out of 1,100 registered diabetes patients in the Viljandi region in 1993 (n=220) were randomly selected and contacted with an invitation for a clinical investigation, of whom 181 (82%) attended in the age groups 15-82 years. In all, 39 patients did not take part due to various reasons including, for example, poor personal economy, ill health, a negative opinion on the study, migration out of the area and transportation problems. Most of the non-attenders lived in the countryside. The proportion of diagnosed type 1 diabetes of our sample (11%) was representative of all the registered diabetes patients.
Clinical investigations
The investigation included the following items: i) a medical history with a focus on diabetes complications; ii) a physical examination (height, weight and office blood pressure), iii) a laboratory investigation (blood glucose, blood glycated haemoglobin (HbAi) serum total and HDL cholesterol and serum creatinine), iv) a 12-lead electrocardiogram (ECG) and v) a self-administered questionnaire on disease-related knowledge and quality of life variables. Proteinuria was measured in only a few patients and the data are therefore not included. Height (m) was measured widiout shoes and weight (kg) in light indoor clothing. The body mass index (BMI) was calculated as kg/m 2 . Blood pressure (mm Hg) was measured twice in a sitting position and a mean of two readings (Korotkoff V) was recorded.
The patients were investigated throughout the day, but blood samples were only taken in the morning. For the determination of fasting blood glucose levels a mobile glucometer ('Reflolux'), was used because the samples were taken at different places, including the patients home. For HbAi measurement a photometric autoanalyser ('Humalyser 815') was used. This parameter was compared with values from a non-diabetic matched control group (n=17), showing a mean HbAi of 4.6% (range 3.2-5.6%).
Questionnaire and medical records
Each patient was also asked to answer a questionnaire on food habits, subjective well-being, 7 recommended medical treatment and a test of diabetes knowledge. The data collection was carried out during the whole year, thus avoiding bias by seasonal variation in food habits. The questionnaire was translated from English into Estonian. In addition, all known diabetes complications were recorded, based on local medical records, including information about the ECGs. In most cases die recommended medical treatment was also followed by the patients, but financial difficulties made it difficult to follow prescriptions all the time for a number of patients. We have no data on details of compliance to prescribed drugs.
Statistics
The results were analysed at the Department for Community Health Sciences at Lund University, Sweden, using an SAS package system. 8 Means and standard deviations (SD) are given. A p-value below 0.05 was regarded as statistically significant when calculating differences between subgroups defined as being in good/ acceptable or poor metabolic control (Student's t-test).
RESULTS
In all, 181 subjects were clinically investigated and completed the questionnaire. The mean duration of diabetes mellitus from time of clinical diagnosis was 10.5 (s.d. 9.7) years for males and 8.0 (7.2) years for females. Type 2 diabetes was diagnosed in 89.5% of the subjects. The clinical characteristics of males and females are shown in taUel. The proportion of patients treated with insulin was 29.8% and with anti-hypertensive drugs 26.5%. Of the insulintreated patients, 55% were also treated with anti-hypertensive drugs. Of all patients 143% were present smokers. The proportion of patients with various diabetes complications was high (73.5%), mostly consisting of different manifestations of cardiovascular disease, which were frequently supported by ECG findings. Foot ulcers or gangrene were observed in 11.6% of the patients The mean HbAi was 7.3% (s.d. 2.4%), with a higher level in males (7-5% and s.d. 2.2%), than in females (7.0% and s.d. 2.4%). The patients were also split into two groups by HbAi levels, where good/acceptable control (HbAi <,1.0%) was found in 49% and poor control (HbAi >7.0%) in 51% of the patients (table 3) . Furthermore, 31 of the participants had an HbAi of <4-5%, implying very good metabolic control. Self-reported food intake did not differ in subgroups of different metabolic control (data not shown). However, a poor diet and a low level of quality of life were registered in many patients, mostly due to self-reported difficult living conditions and socioeconomic problems (table 4). Knowledge about diabetes was very variable among patients and, therefore, difficult to interpret, but did not seem to differ between subjects in good or poor metabolic control (table 3). 
DISCUSSION
Metabolic control
The main finding of this study was that the metabolic control of diabetes patients from Viljandi was far from perfect but better than we expected. The glycated haemoglobin (HbAi) assay is used to assess metabolic control in diabetes patients and the glycated haemoglobin levels in these subjects usually correlated well with their mean levels of blood glucose. In soudiem Sweden, a local study in six primary health care areas, including 1,861 diabetes patients, reported results of mean glycated haemoglobin Aic (normal range 4.0-5.8%) of 7.0% 9 and in another study of 7.1%. 10 This is quite similar to what has been described in this Estonian study widi a mean HbAi of 7.3%, even if the laboratory mediods used for tiie measurement of glycated haemoglobin were not completely identical. However, die proportion of diabetes complications is supposed to be high or even higher in Estonia dian found in similar studies from Sweden 9 "'' and the Nordic countries, mostly consisting of macrovascular complications.
Duration of diabetes and prevalence of complications
The mean duration of diabetes in our study was 8.9 years. The data collection of diabetes duration and medical history was based on retrospective analyses using die medical records of different policlinics (healfJi centres) where die patients have been treated. The true duration of diabetes may in fact have been longer. It is also quite possible diat some cardiovascular diagnoses were present before die onset of diabetes and, dius, not defined as a complication of diabetes, e.g. pre-diabetic hypertension. Furthermore, some of die patients widi congestive heart failure may have been overdiagnosed due to lack of strict diagnostic criteria in die local healdi care system. On die odier hand, die prevalence of neuropadiy may have been underdiagnosed due to neglect or lack of clinical procedures for detecting it. The prevalence of hypertension may also have been underdiagnosed if older, less strict blood pressure criteria for hypertension were used in previous years at die local healdi care level. Diabetes mellitus and cardiovascular disease are major public healdi problems in Estonia as well as in the odier Nordic countries. In Estonia the prevalence of type 1 diabetes is approximately 1.7 per 1,000 inhabitants (T. Poodar, personal communication). The prevalence of type 1 diabetes is not low, but is certainly not as high as Ln Finland where the population is edinically and 12 The overall prevalence rates of diabetes complications in most countries are 40-50% for hypertension and 30-35% for heart diseases. The Swedish population-based complication rates in diabetes are hypertension (48%), cardiovascular disease (29%), congestive heart failure (15%), neuropadiy (37%) and clinical nephropadiy (9%), according to a population-based study. 9 Awareness of diabetes meUitus The results of studies from different countries show diat many adult patients are not aware of dieir diabetes. Diabetes is often diagnosed by chance and it may already have been present for a long time at die time of diagnosis. A considerable proportion of Estonian diabetes patients are diagnosed in hospital or at the policlinic following a stroke, myocardial infarction or foot problems, which suggest diat their diabetes has passed undetected for years.
Metabolic control and food habits
The interrelationship between increasing age, poor metabolic control and cardiovascular disease complications is theoretically not surprising. Hyperglycaemia may contribute in many ways to bodi adierosclerosis and dirombotic disease and is of importance for overall mortality even at old age. 14 However, no association was seen between the degree of metabolic control and food habits (data not given). It may be possible diat answers were not fully correct, because most diabetics, particullarly of old age, do not count dieir food items and have difficulties in remembering how much diey have really eaten. There is also a possibility diat Estonia is not yet much Westernised according to food habits. This is particullarly relevant for the soudiern part of die country where food habits are radier poor and similar for most people in die countryside; no sweets or chips are consumed, but mostly black rye bread, potatoes and skimmed milk.
Quality of life of diabetes patients
An impaired quality of life is associated widi diabetes mellitus in Estonia and seems to be lower than in Sweden based on two recent studies in diabetes patients. 15il6 The
Estonian figures on quality of life were also lower than figures from patients at a Swedish surgical department, who would be expected to have a lower than normal quality of life. 17 Social and financial problems add to die burden on quality of life of many elderly Estonians. A chronic disease such as diabetes implies a multitude of personal and medical problems for the individual patient in most countries, even though die problems are relative to the problems of die non-diabetic population, for whom we regretfully lack quality of life data in Estonia. However, the standard of health care and access to medication differ between countries and, thus, the capacity for dealing with these problems.
CONCLUSIONS
Diabetes patients in Viljandi, Estonia, showed an acceptable degree of metabolic control, but reported a high degree of diabetes complications, as well as an impaired quality of life. The diabetes complications may therefore be due to detrimental factors other than hyperglycaemia, e.g. their standard of care during previous years as well as the current socioeconomic and living conditions. This project was supported by the Medical Faculty, University of Lund and the Swedish Medical Association.
